论文部分内容阅读
目的:通过分析狼疮肾炎(LN)患者住院时、激素治疗后、加用他汀类降脂药治疗前后血脂的变化特点,为临床诊治提供有利的参考依据。方法:对59例LN患者进行血脂异常情况及发病率的对比分析,动态观察不同药物治疗前后组内血脂变化情况。结果:59例LN患者血脂异常发病率为72.9%,其中既往未用激素治疗者血脂异常发病率为60.6%,既往应用激素治疗者发病率为88.5%,两组发病率经X2检验,X2=4.39>3.84,P>0.05,差异有显著性。并分别与我国成人血脂异常患病率18.5%进行比较,前组与其比较X2=35.92>3.84,P<0.05,差异有显著性;后组与其比较χ2=79.24>3.84,P<0.05,差异有显著性。LN患者应用糖皮质激素治疗后,总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)随治疗时间的延长而呈现升高趋势,差异有显著性。LN患者应用糖皮质激素同时加用阿托伐他汀治疗后,TC、LDL-C随治疗时间的延长而呈现下降趋势,差异有显著性。甘油三酯(TG)在各组治疗后与治疗前比较,差异无统计学意义。结论:LN患者无论是否应用激素治疗均存在明显的血脂异常,同时激素参与LN治疗过程中血脂异常的发生机制,是导致血脂异常的原因之一。
Objective: To provide a favorable reference for the clinical diagnosis and treatment of lupus nephritis (LN) by analyzing the changes of blood lipid in patients with lupus nephritis (LN) before and after treatment with hormonal therapy plus statins lipid-lowering drugs. Methods: 59 cases of LN patients with dyslipidemia and incidence of comparative analysis of dynamic changes in different groups before and after treatment of blood lipid levels. Results: The incidence of dyslipidemia in 59 patients with LN was 72.9%. The incidence of dyslipidemia was 60.6% in patients without hormone therapy and 88.5% in patients with previous hormone therapy. The morbidity of X2 in the two groups was X2 = 4.39> 3.84, P> 0.05, the difference was significant. And compared with the prevalence of adult dyslipidemia in our country 18.5%, compared with the former group X2 = 35.92> 3.84, P <0.05, the difference was significant; the latter group compared with χ2 = 79.24> 3.84, P <0.05, the difference was Significance. After treatment with glucocorticoid, the total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) increased with the prolongation of treatment time in LN patients, the difference was significant Sex. LN patients with glucocorticoid plus atorvastatin treatment at the same time, TC, LDL-C with the extension of treatment time showed a downward trend, the difference was significant. Triglyceride (TG) in each group after treatment compared with before treatment, the difference was not statistically significant. CONCLUSION: LN patients have obvious dyslipidemia whether hormone therapy is applied or not. At the same time, the pathogenesis of dyslipidemia during hormone therapy is one of the causes of dyslipidemia.